These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18378711)

  • 1. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
    Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
    J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
    Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
    Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
    J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O; Heredia A; Gallo RC; Reitz M; Le N; Redfield RR
    Antiviral Res; 2009 Jul; 83(1):86-9. PubMed ID: 19501260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
    Tilton JC; Amrine-Madsen H; Miamidian JL; Kitrinos KM; Pfaff J; Demarest JF; Ray N; Jeffrey JL; Labranche CC; Doms RW
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):13-24. PubMed ID: 20055594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
    Asin-Milan O; Sylla M; El-Far M; Belanger-Jasmin G; Haidara A; Blackburn J; Chamberland A; Tremblay CL
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7565-9. PubMed ID: 25267674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
    Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
    Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
    Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
    J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
    Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
    AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF; Sparks SS; Schell K; Shibayama S; McDanal CB; Fang L; Adkison KK; Shachoy-Clark A; Piscitelli SC
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
    Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.